Previous 10 | Next 10 |
IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the secon...
2023-07-17 01:18:44 ET Summary Reneo Pharmaceuticals, developing therapies for rare genetic mitochondrial diseases, has been added to the Russell 3000 index and raised around $55 million through a recent public offering. RPHM's primary product, mavodelpar, has shown promise in tri...
2023-07-03 08:41:08 ET PainReform ( PRFX ) +22% . Alvotech ( ALVO ) +19% . Ensysce Biosciences ( ENSC ) +12% . Alliance Entertainment ( AENT ) +10% . Great Ajax AJX +9% on plans to be acquired by Ellington Financial for $7.33...
IRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s ma...
2023-06-26 12:17:40 ET Pharmaceutical company Reneo Pharmaceuticals ( NASDAQ: RPHM ) said on Monday that it has been added to the broad-market Russell 3000 index at the conclusion of the 2023 Russell indexes annual reconstitution. The addition is effective from June 26, after ...
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has been added to the ...
IRVINE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present ...
IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s manag...
IRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s manag...
2023-05-11 09:54:06 ET Reneo Pharmaceuticals press release ( NASDAQ: RPHM ): Q1 GAAP EPS of -$0.60 in-line. Raised $68.3 million in gross proceeds from a concurrent public offering and private placement in May 2023 For further details see: Reneo Pharmaceuticals G...
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...